Long-term administration of maxadilan improves glucose tolerance and insulin sensitivity in mice

  • Yu R
  • Yi T
  • Xie S
 et al. 
  • 1


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Maxadilan and its truncated variant, M65, are agonist and antagonist specific, respectively, for the PAC1 receptor. PAC1 is the specific receptor for the pituitary adenylate cyclase-activating peptide (PACAP), which is not shared by vasoactive intestinal peptide (VIP). PACAP is a ubiquitous peptide of the glucagon superfamily that is involved in glucose homeostasis and regulation of insulin secretion. This study employed the recombinant maxadilan and M65 to evaluate the PAC1 receptor-mediated effects on energy metabolism using NIH mice. First, the acute effect of maxadilan-induced hyperglycemia was blocked by M65. In long-term studies, NIH mice were given daily intraperitoneal injections with maxadilan, M65, or vehicle for 21 days. Maxadilan suppressed feeding and enhanced water intake significantly for the first several days. After that period, maxadilan treatment continued to promote food and water intake. Long-term administration of maxadilan led to an increase in body weight (P

Author-supplied keywords

  • Insulin
  • Mice
  • PM 2008 18
  • adverse effects
  • metabolism

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

There are no full text links


  • R Yu

  • T Yi

  • S Xie

  • A Hong

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free